Flecainide Hepatotoxicity Management

Monitoring and Prevention

• Baseline liver function tests should be obtained before initiating flecainide therapy, and regular monitoring of hepatic function is recommended during treatment, particularly in patients with pre-existing liver disease or those taking other hepatotoxic medications, as recommended by the American College of Cardiology 1
• Patients taking multiple hepatotoxic medications concurrently with flecainide are at increased risk, and minimizing concomitant use of other hepatotoxic medications is recommended 1

Treatment and Alternative Therapies

• Consider alternative antiarrhythmic agents such as amiodarone, sotalol, or beta-blockers depending on the clinical scenario, as suggested by the American Heart Association 2, 3
• Flecainide should not be administered for treatment of SVT in adult congenital heart disease patients with significant ventricular dysfunction, according to the American College of Cardiology 5

Safety Considerations

• Beyond hepatotoxicity, flecainide has other significant risks including proarrhythmic effects, particularly in patients with structural heart disease or coronary artery disease, as reported by the American Heart Association 2, 4
• Regular ECG monitoring is essential during flecainide therapy to detect potential cardiac conduction abnormalities, as recommended by the American College of Cardiology 4